Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunStone: Obexelimab in Systemic Lupus Erythematosus
NCT06559163Phase 2Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Obexelimab with Placebo (2 arms). Primary endpoint: Primary Outcome Measure at 24 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06559163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559163.